Welcome to our website
Here you will find an extensive collection of references and publications that reflect our passion for cutting-edge research and innovation in the field of medical technology. Our activities are divided into the areas of basic research, experimental studies, clinical studies, product development and public funding projects.
All published information can also be found at PubMed
INNORA GMBH
Referenzen & Publikationen
Erfahren Sie mehr über unsere Arbeit & Publikationen im Bereich der Medizintechnik.
BASIC RESEARCH
Research work forms the foundation of our innovative products and solutions. In this section you will find references to scientific articles and publications that our team has published. Basic research is the starting point for the development of groundbreaking technologies that drive medical technology forward.
Cremers B, Toner JL, Schwartz LB, von Oepen R, Speck U, Kaufels N, Clever YP, Mahnkopf D, Böhm M, Scheller B.
Inhibition of neointimal hyperplasia with a novel Zotarolimus coated balloon catheter.
Clin Res Cardiol. 2012; 101: 469-476 [PubMed]
Speck U, Cremers B, Kelsch B, Biedermann M, Clever YP, Schaffner S, Mahnkopf D, Hanisch U, Böhm M, Scheller B.
Does pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel?
Circ Cardiovasc Interv. 2012;5:392-400 [PubMed]
Cremers B, Kelsch B, Clever YP, Hattangadi N, Mahnkopf D, Speck U, Taupitz M, Scheller B.
Inhibition of neointimal proliferation after bare metal stent implantation with low-pressure drug delivery using a paclitaxel-coated balloon in porcine coronary arteries.
Clin Res Cardiol. 2012; 101: 385-391 [PubMed]
EXPERIMENTAL STUDIES
Here you will find publications resulting from our experimental clinical studies.
Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Böhm M, Hamm B.
Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries.
Radiology. 2006;240:411-418 [PubMed]
Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G.
Paclitaxel balloon coating - a novel method for prevention and therapy of restenosis.
Circulation. 2004; 110: 810-814 [PubMed]
Scheller B, Speck U, Schmitt A, Böhm M, Nickenig G.
Addition of Paclitaxel to contrast media prevents restenosis after coronary stent implantation.
J Am Coll Cardiol 2003; 42: 1415-1420 [PubMed]
Scheller B, Speck U, Romeike B, Schmitt A, Sovak M, Böhm M, Stoll HP.
Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model.
Eur Heart 2003; 24: 1462-1467 [PubMed]
Clauss W., Scheller B., Schmitt A., Sovak M., Speck U.
No difference among modern contrast media’s effect on neointimal proliferation and restenosis following coronary stenting in pigs.
Invest Radiol 2003; 38: 743-749 [PubMed]
Speck U., Scheller B., Puls R., Stroszczynski C.
Paradigms and perspectives in contrast media research. Harry Fischer Memorial Lecture.
Acad Radiol 2002;9 (suppl 2): S 392-397 [PubMed]
Scheller B, Speck U, Schmitt A, Clauss W, Sovak M, Böhm M, Stoll HP.
Acute cardiac tolerance of current contrast media and the new taxane protaxel using iopromide as carrier during porcine coronary angiography and stenting.
Invest Radiol 2002; 37: 29-34 [PubMed]
CLINICAL STUDIES
We are committed to evidence-based medical advances. Here you will find publications resulting from our clinical studies. Collaboration with leading medical experts and clinics enables us to validate the safety, efficacy and performance of our developments in real clinical scenarios.
Tepe G, Schnorr B, Albrecht T, Brechtel K, Claussen CD, Scheller B, Speck U, Zeller T.
Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-years follow-up of the THUNDER trial.
J Am Coll Cardiol Intv 2015;8:102–108 [PubMed]
Werk M, Albrecht T, Meyer R-D, Ahmed MN, Behne A, Dietz U, Eschenbach G, Hartmann H, Lange C, Schnorr B, Stiepani H, Biondi Zoccai G, Lopez Hänninen E.
Paclitaxel-coated balloons reduce restenosis after femoro- popliteal angioplasty. Evidence from the randomized PACIFIER trial.
Circ Cardiovasc Interv. 2012;5: [PubMed]
Scheller B, Clever YP, Kelsch B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Speck U, Böhm M, Cremers B.
Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel coated balloon catheter.
JACC Cardiovasc Interv. 2012; 5: 323-330 [PubMed]
Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U.
Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg.
N Engl J Med. 2008;358:689-699. [PubMed]
Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U.
Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.
N Engl J Med. 2006;355:2113-2124. [PubMed]
PRODUCT DEVELOPMENT
Our product developments are the result of intensive research work. Here we present specialist articles and publications that have been published in connection with product developments.
Clever YP, Peters D, Calisse J, Bettink S, Berg M-C, Sperling C, Stoever M, Cremers B, Kelsch B, Bohm M, Speck U, Scheller B.
Novel Sirolimus–coated balloon catheter. In vivo evaluation in a porcine coronary model.
Circ Cardiovasc Interv. 2016;9:e003543. DOI: 10.1161/CIRCINTERVENTIONS.115.003543 [PubMed]
Kelsch B, Scheller B, Biedermann M, Clever YP, Schaffner S, Mahnkopf D, Speck U, Cremers B.
Dose-response to paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model.
Invest Radiol. 2011;46:255-263 [PubMed]
Cremers B, Speck U, Kaufels N, Mahnkopf D, Kühler M, Böhm M, Scheller B.
Drug-eluting balloon: Very short-term exposure and overlapping.
Thromb Haemost. 2009;101:201-206 [PubMed]
PUBLICLY FUNDED PROJECTS
Publications and reports on our participation in public projects and partnerships.
perKunSt
Development of personalized biodegradable plastic stents
plastic stents
Duration: 01.01.2023 - 31.12.2025
Brief project description
Arteriosclerosis is caused by a pathological deposition of fats in the inner layers of arterial blood vessels and is considered the most common cause of coronary heart disease. The implantation of stents has become established as a local measure for arteriosclerosis. Despite the high demands placed on the reliability and materials of coronary stents, pathological phenomena such as restenosis, stent thrombosis or chronic immune reactions can occur after implantation. Resorbable stents made of biodegradable polymers are considered a promising approach to circumvent these disadvantages, but still require further intensive research. This includes the evaluation of innovative stent materials and geometries.
The aim of the project is to develop personalized stents based on biodegradable plastics. Their use should contribute to improving the quality of life of patients by reducing complications following coronary stent implantation. Two main sub-goals are being pursued:
- Development of a 3D printer with an innovative workpiece clamping system for the production of novel plastic stent designs
- Evaluation and application of biodegradable plastics for the production of resorbable stents with degradation gradients
The overall aim of the project is to improve the quality of life of patients by reducing complications following coronary stent implantation. To this end, methods for modifying the geometry of the stent and coating technologies for targeted drug release are being researched.
The project is focused on the production of resorbable stents, but the results are also transferable to other implants. The combination of research into innovative, biocompatible plastics and their processing in a developed 3D printing system for the production of filigree structures with defined degradation times can be used in many areas of medical technology.
Project partner:
Organical CAD/CAM GmbH
InnoRa GmbH
Fraunhofer IPK
Funding:
This project is funded by Investitionsbank Berlin and co-financed by the European Regional Development Fund (ERDF).
The funding is part of the 1st Berlin Pro FIT Call “AMBER - Additive Manufacturing in the fields of: Personalized Medical Technology, Construction and Lightweight Construction, Additive Manufacturing with Bio-based Materials and Additive Manufacturing in/for Space”.
